The trial, involving 39 healthy volunteers, tested a vaccine designed to provide protection against multiple Sarbeco coronaviruses—the large group of viruses that occur in nature including SARS-CoV-2, which caused the COVID pandemic.

The vaccine triggered immune responses in the volunteers not only to SARS-CoV-2 and SARS, but to related bat viruses that could potentially jump from animals to humans and cause future pandemics.

This trial proves the safety of an entirely new way of designing vaccines. The technology uses an AI-designed “super antigen” to provide lasting protection against a broad range of viruses—for example the Ebola group, or Sarbeco coronavirus group—even as they mutate.